Lupin specializes in the research, development, manufacturing, and distribution of a wide range of pharmaceutical products, including both generic and branded medications, biosimilars, and specialty products. The company has a significant presence in the U.S., Europe, and Asia and operates in more than 100 countries.
Lupin’s product portfolio includes a wide range of medications, including those used to treat cardiovascular disease, diabetes, oncology, respiratory disorders, and women’s health issues. The company has also developed and commercialized several first-to-file and first-to-market generic drugs.
Lupin’s Australia-based unit has received approval to market a medication for the management of chronic obstructive pulmonary disease (COPD) and asthma. It is important to note that COPD and asthma are two separate respiratory conditions that share some symptoms, such as difficulty breathing and wheezing, but have different underlying causes and treatment options.
Asthma is a long-term respiratory condition that impacts a significant portion of the global population. The goal of asthma treatment is to manage symptoms, prevent exacerbations, and improve quality of life. Asthma medications can be delivered through various devices, such as inhalers, nebulizers, and tablets.
The approval from TGA indicates that the medication has met the necessary safety and efficacy standards for use in Australia. It is important to note that Tiotropium should only be used under the supervision of a healthcare provider and that patients should follow the instructions for use carefully.
Generic Health Pvt Limited’s approval to market Tiotropium 18 micrograms powder for inhalation provides an additional treatment option for patients with COPD in Australia, potentially increasing access to this important medication. Lupin has stated that the approved product will be manufactured at their facility located in Pithampur.
Manufacturing the product at a facility owned by the company provides Lupin with greater control over the production process, ensuring that the medication is manufactured according to the necessary quality standards. This can help to ensure that the medication is safe and effective for patients to use.
By manufacturing the product at their facility, Lupin can potentially increase their supply of the medication and ensure that it is readily available for patients who need it. Tiotropium is a type of bronchodilator medication that works by relaxing the muscles in the airways, making it easier to breathe. The medication is inhaled using a dry powder inhaler called a loop inhaler. The recommended dose is one capsule (18 micrograms) per day, which should be used at the same time each day.
Lupin Statements
Tiotropium bromide is generally well-tolerated. These side effects are usually mild and go away on their own. Tiotropium bromide is a safe and effective treatment for COPD. It is important to talk to your doctor about the risks and benefits of tiotropium bromide before starting treatment.
According to Lupin’s President-Legal for Canada, Australia, and Japan, Sofia Mumtaz, the approval of their medication for the treatment of chronic obstructive pulmonary disease (COPD) by the Therapeutic Goods Administration (TGA) is a significant achievement for the company’s commitment to providing affordable treatment options to patients in Australia.
By offering a high-quality and cost-effective medication, Lupin aims to facilitate access to complex generics for patients in the respiratory therapeutic area. This approval represents a milestone in the company’s ongoing efforts to make medicines accessible to those who need them. The availability of this medication can potentially provide healthcare professionals in Australia with an additional treatment option to help manage COPD, ultimately benefiting patients who require this medication.
